{'fraction_non_alphanumeric': 0.024013722126929673, 'fraction_numerical': 0.010291595197255575, 'mean_word_length': 5.212765957446808, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[EBM for the PTH treatment of osteoporosis].

In clinical trials in postmenopausal osteoporosis, PTH administration consistently increased BMD in the lumbar spine and femoral neck. In fracture study, PTH decreased the risks of the incident vertebral fractures to 35% and non-vertebral fractures to 47% in 18 months. Reductions in fracture risks continued in a year after discontinuation of the treatment. While osteosarcoma was developed by life-long administration in rats, PTH action certainly plays the significant role as a new therapeutic agent in the treatment of osteoporosis.